Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo

Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo: A Double Blind Randomized Clinical Trial

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01890538

Enrollment

Registered

2013-07-01

Start date

2013-06-30

Completion date

2014-05-31

Last updated

2014-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Vertigo

Keywords

vertigo, dimenhydrinate, piracetam

Brief summary

This study aims to investigate efficacy of two different intravenous drugs (dimenhydrinate and piracetam) in the symptomatic management of peripheral vertigo. The patients will be randomized in two groups according to symptomatic treatment modalities: Dimenhydrinate (100 mg) and piracetam (2 g) will be given in 100 cc normal saline in 30 minutes. Each patient will be asked if her/his vertigo symptoms resolved or not, according to a numeric rating scale (0=no vertigo, 10=worst possible vertigo). The patient will be rate the intensity of symptoms in the following times: * Numeric rating scale (1 to 10): Admission * Numeric rating scale (1 to 10): After the study drug (No ambulation)\* * Numeric rating scale (1 to 10): After the study drug (Ambulation)\* * Ambulation refers to head movements or walking in the room, if applicable.

Interventions

DRUGAdministration of 100 mg dimenhydrinate intravenous

DRUG2 g piracetam intravenous

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Presenting to emergency department with vertigo symptoms * Adult patients (over 18) * Agree to participate to study (understanding the study protocol and signing the informed consent form)

Exclusion criteria

* Patients under 18 years * Patients diagnosed with ischemic/hemorrhagic stroke after neuroimaging * Patient diagnosed with transient ischemic attack * Pregnants * Patients taking any analgesics or antihistaminic drugs last 24 hours * Documented or declared allergy to dimenhydrinate, piracetam or benzodiazepines * Patients who do not agree to participate to the study

Design outcomes

Primary

Measure	Time frame
Change in numeric rating scale	Change from baseline in numeric rating scale at 30th minute

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026